Global Haemophilia Treatment Market Research Report 2022

Haemophilia is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.
Due to the COVID-19 pandemic, the global Haemophilia Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Haemophilia Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Haemophilia Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Haemophilia A accounting for % of the Haemophilia Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Haemophilia Treatment include Bayer, Novo Nordisk, Pfizer, Roche, Aptevo Therapeutics, Catalyst BioSciences, Dimension Therapeutics, Takeda and CSL Behring and etc. In terms of revenue, the global 3 largest players have a % market share of Haemophilia Treatment in 2021.
This report focuses on Haemophilia Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Haemophilia Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Haemophilia Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Haemophilia A
Haemophilia B
Segment by Application
Hospital
Pharmaceutical Companies
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Bayer
Novo Nordisk
Pfizer
Roche
Aptevo Therapeutics
Catalyst BioSciences
Dimension Therapeutics
Takeda
CSL Behring
Alnylam Pharmaceuticals

Frequently Asked Questions



This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

  • By product type
  • By End User/Applications
  • By Technology
  • By Region

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Please Select a Format

market Reports market Reports